% | $
Quotes you view appear here for quick access.

Alkermes plc Message Board

  • genetics4rfuture genetics4rfuture Oct 12, 2010 9:04 PM Flag


    Right now, only some people are excited about this drug approval and most think that it is "not very important" to ALKS's future revenue stream.


    They are basing this decision on the fact that Vivitrol is already available for "off label" use by doctors and it was not prescribed heavily. I wonder why? It costs 1,000/mo and you have to pay for it out of your own pocket with zero Insurance compensation!!

    But now everything has changed. Nearly 100% of standard HMO and PPO plans that Americans get in the workplace and Medicare will now be paying that fee and doctors are free to prescribe it en masse without scrutiny.

    Whether the market figures it out slowly as the orders and prescriptions for Vivitrol beat all expectations, or they figure it out quickly by simply getting a clue; the fact is ALKS is severely undervalued as of right now AH and will have a 20 or maybe 30 handle on it very soon.

    Best of Luck with your choices and grab this thing first thing in the pre-market.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes, and supports your opinion:
      The Partnership at Comments on FDA Approval of Alkermes Opioid Dependence Medication

      NEW YORK, Oct. 13 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration's approval of Alkermes' opioid dependence medication (VIVITROL) for the prevention of relapse to opioid dependence following opioid detoxification is positive news for families of young adults and all those who are struggling to overcome opioid addiction. Addiction, a disease of the human brain, is a chronic illness while opioid dependence is frequently characterized by relapse.

      "Opioid dependence, whether from misuse of prescription pain medications or illicit use of heroin, is one of the most imperative health issues facing our nation, and as an organization, we have devoted significant resources to help families find appropriate treatment for a loved one with an addiction and support that person in recovery," said Steve Pasierb, President and Chief Executive Officer of The Partnership at "This new indication for Alkermes' product as a non-addictive approach to prevent relapse to opioid dependence in people age 18 and older brings hope to the families we serve. Our view is that this medication must be used in concert with appropriate addiction treatment services and psychosocial support."

      Parents are at the center of the organization's mission, and The Partnership at recently unveiled a new name and expanded resources, providing them with answers and support at whatever their stage of need, from prevention to recovery. Among these new offerings are dedicated treatment resources on, and specifically, Time To Get Help, a comprehensive tool that includes information on how to obtain a proper assessment, identify and pay for appropriate treatment and connect with other parents who have had their own family experiences with substance abuse and addiction.

      Recognizing that 11 million American adolescents and young adults, ages 12-29, need help with drug and alcohol problems and almost 23 million people in the U.S., age 12 or older, are struggling with substance abuse,(1) The Partnership at worked with parents and experts in the field of substance abuse, treatment and recovery to create Time To Get Help. This new treatment resource and community helps parents and caregivers gain a better understanding of teen alcohol and drug abuse, dependence and addiction; get support from experts and other parents who have been there and understand the challenges and emotions of caring for an addicted child; and find the right treatment for their child and family.

      Visit to learn more about various programs and resources on prevention, intervention, treatment, recovery and community education from The Partnership at

      The Partnership at is a nonprofit organization that helps parents prevent, intervene in and find treatment for drug and alcohol use by their children. Bringing together renowned scientists, parent experts, and communications professionals, this public health nonprofit translates current research on parenting, teen behavior, addiction and treatment into easy to understand resources at Through its PACT360 nationwide Community Education Program, the nonprofit educates and mobilizes local community efforts to address drug threats at the grassroots level, including methamphetamine and prescription drug abuse, and also provides parent training and teen programs that help prevent teen substance abuse. The organization depends on donations from individuals, corporations, foundations and government and is thankful to SAG/AFTRA and the advertising and media industries for their ongoin9 National Survey on Drug Use and Health, SAMHSA

    • youschmuck Oct 12, 2010 10:21 PM Flag

      I'm holding until European big pharma comes along and scoops up the company. This has EUROPE written all over it!!

42.28-1.47(-3.36%)Jun 24 4:00 PMEDT